This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Friday's Health Winners & Losers

ICAgen's (ICGN) shares sank 71% to $1.22 after the company said it would discontinue studies of a drug intended to treat sickle-cell disease in certain patients. The decision followed an analysis of one of its clinical trials by an independent data-monitoring committee. The company will immediately enter an eight-week follow-up period.

Shares of Cell Genesys (CEGE) lost 8.3% following its earnings report after the close of trading on Thursday. The company reported quarterly revenue of $1.05 million compared with $2.78 million a year ago. Cell Genesys lost $27.9 million, or 60 cents a share, in the second quarter, compared with a loss of $27.4 million, or 60 cents a share, a year earlier. Analysts were expecting the company to lose 62 cents a share. The stock was recently trading at $4.54.

Amgen (AMGN) fell a day after the company said a federal appeals court reversed a decision on two patent disputes with Transkaryotic Therapies. The federal court did affirm a lower court's decision that Transkaryotic and Aventis Pharmaceuticals infringed Amgen's patent on its anemia drug Epogen. Shares were down 3.1% to $68.73.

Shares of Osteotech (OSTE) rose after the company said it swung to a profit for the second quarter. Osteotech earned $800,000, or 4 cents a share, compared with a loss of $1.9 million, or 11 cents a share, a year earlier. Revenue remained flat at $25.3 million. Shares were up 10.1% to $4.15.

Adeza Biomedical (ADZA), a maker of women's health products, gained 11.3% to $16.64 following its earnings report after the close of trading Thursday. For the second quarter, the company reported record sales of $13 million, up 23% from a year ago. Net income in the quarter reached $537,000, or 3 cents a share, including stock-based compensation expenses.

Other health stocks on the move included Acorda Therapeutics (ACOR), up 8.8% to $3.34; Immtech Pharmaceuticals (IMM), gaining 7.4% to $5.78; Genentech (DNA), rising 1.1% to $81.26; ViaCell (VIAC), up 3.5% to $3.84; CuraGen (CRGN), adding 3.9% to $3.17; and Oscient Pharmaceuticals (OSCI), up 16.8% to $1.25.

Meanwhile, Novacea (NOVC), shares took a 10.2% hit to $7.35; Orthologic's (OLGC), shares fell 6.1% to $1.54; and CoTherix (CTRX), was down 2.6% to $7.22.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs